Who are Cultured autologous keratinocytes's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, RAK therapy, Licartin and CIK, Cord Blood Cell, hUCB, SkinTE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cultured-autologous-keratinocytes.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cultured autologous keratinocytes — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cultured autologous keratinocytes (Cultured autologous keratinocytes) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy; autologous cellular product. Area: Dermatology; Wound Care; Burn Treatment.

phase 3 Cell therapy; autologous cellular product Dermatology; Wound Care; Burn Treatment Biologic Live · refreshed every 30 min

Target snapshot

Cultured autologous keratinocytes (Cultured autologous keratinocytes) — Association of Dutch Burn Centres. Cultured autologous keratinocytes are patient-derived skin cells grown in vitro and applied topically to promote wound healing and skin regeneration in severe burn injuries.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cultured autologous keratinocytes TARGET	Cultured autologous keratinocytes	Association of Dutch Burn Centres	phase 3	Cell therapy; autologous cellular product
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
RAK therapy	RAK therapy	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Cell therapy
Licartin and CIK	Licartin and CIK	Tianjin Medical University Cancer Institute and Hospital	marketed	Monoclonal antibody (Licartin); Adoptive cell therapy (CIK)	HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)
Cord Blood Cell	Cord Blood Cell	China Spinal Cord Injury Network	marketed	Cell therapy
hUCB	hUCB	StemCyte Taiwan Co., Ltd.	marketed	Allogeneic hematopoietic stem cell therapy
SkinTE	SkinTE	PolarityTE	marketed	Autologous cell therapy / Tissue-engineered product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy; autologous cellular product class)

Association of Dutch Burn Centres · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cultured autologous keratinocytes — Competitive Intelligence Brief. https://druglandscape.com/ci/cultured-autologous-keratinocytes. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab